SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indicati…
$8.42+6.85%
报价 2026-11-06
市值
$1.7B
EV
$2.28B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -45.5%
$1.39$15.46
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SLSSELLAS Life Sciences Group, Inc. | $1.7B | +6.9% | +12.8% | 0% | – | – | – | |
| OABIOmniAb, Inc. | $733.7M | +4.1% | +58.0% | 63.6% | – | – | 312.2x | |
| CCCCC4 Therapeutics, Inc. | $381.4M | +5.1% | -25.0% | 94.9% | – | – | – | |
| PRLDPrelude Therapeutics Incorporated | $208.4M | +1.3% | +56.0% | 98.3% | – | – | – | |
| MDWDMediWound Ltd. | $184M | +6.9% | – | 19.2% | – | – | – | |
| IVVDInvivyd, Inc. | $165.9M | -3.8% | +64.0% | 91.4% | – | – | – | |
| TARAProtara Therapeutics, Inc. | $135.9M | +8.0% | -10.4% | 0% | – | – | – | |
| ARMPArmata Pharmaceuticals, Inc. | $130.5M | +17.0% | +13.3% | 68.2% | – | – | – | |
| CDXSCodexis, Inc. | $118.3M | +5.9% | +10.1% | 79.5% | – | – | – | |
| 同行中位数 | – | – | +13.3% | 73.9% | – | – | 312.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。